2025 / 06

Next Paper
DOI: 10.24075/brsmu.2025.077
Copyright: © 2025 by the authors. Licensee: Pirogov University.
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (CC BY).

ORIGINAL RESEARCH

Antiviral activity of mRNAS encoding intracellular scFv antibodies against conserved influenza virus epitopes

Plotnikova MA , Oleynik VA , Klotchenko SA
About authors

Smorodintsev Research Institute of Influenza, St. Petersburg, Russia

Correspondence should be addressed: Sergey A. Klotchenko
Professora Popova, 15/17, Saint Petersburg, 197022, Russia; ur.liam@kitafsof

About paper

Funding: This study was supported by financially by the Russian Science Foundation, Agreement No. 24-25-00488: "Study of the antiviral potential of intracellular scFv antibodies against influenza virus" (supervisor — S.A. Klotchenko), https://rscf.ru/project/24-25-00488/

Author contribution: Plotnikova MA — design of structures, conducting experiments, registration and analysis of results, statistical processing, manuscript authoring and formatting; Oleynik VA — conducting experiments, registration of results; Klotchenko SA — study design, preparation and characterization of mRNA preparations, conducting experiments, registration and analysis of results, manuscript editing.

Received: 2025-11-27 Accepted: 2025-12-10 Published online: 2025-12-26
|
  1. Bender RG, et al. Global, regional, and national incidence and mortality burden of non-COVID-19 lower respiratory infections and aetiologies, 1990–2021: a systematic analysis from the Global Burden of Disease Study 2021. The Lancet Infectious Diseases. 2024; 24 (9): 974–1002. Available from: https://doi.org/10.1016/S1473-3099(24)00176-2.
  2. Lin JJ, Feramisco JR. Disruption of the in vivo distribution of the intermediate filaments in fibroblasts through the microinjection of a specific monoclonal antibody. Cell. 1981; 24 (1): 185–93. Available from: https://doi.org/10.1016/0092-8674(81)90514-6.
  3. Blose SH, Meltzer DI, Feramisco JR. 0-nm Filaments Are Induced to Collapse in Living Cells Microinjected with Monoclonal and Polyclonal Antibodies Against Tubulin. Journal of Cell Biology. 1984; 98: 847–58. Available from: https://doi.org/10.1083/jcb.98.3.847.
  4. Kallajoki M, et al. Microinjection of a monoclonal antibody against SPN antigen, now identified by peptide sequences as the NuMA protein, induces micronuclei in PtK2 cells. Journal of Cell Science. 1993; 104 (1): 139–50. Available from: https://doi.org/10.1242/jcs.104.1.139.
  5. Rabbitts TH. Intracellular Antibodies for Drug Discovery and as Drugs of the Future. Antibodies. 2023; 12 (1). Available from: https://doi.org/10.3390/antib12010024.
  6. Biocca S, Neuberger MS, Cattaneo A. Expression and targeting of intracellular antibodies in mammalian cells. The EMBO Journal. 1990; 9 (1): 101–8. Available from: https://doi.org/10.1002/j.1460-2075.1990.tb08085.x.
  7. Marschall ALJ, Dübel S, Böldicke T. Recent advances with ER targeted intrabodies. Advances in Experimental Medicine and Biology. 2016; 917: 77–93. Available from: https://doi.org/10.1007/978-3-319-32805-8_5.
  8. Gerondopoulos A, et al. A signal capture and proofreading mechanism for the KDEL-receptor explains selectivity and dynamic range in ER retrieval. eLife. 2021; 10. Available from: https://doi.org/10.7554/eLife.68380.
  9. Johnson AE, Van Waes MA. The Translocon: A Dynamic Gateway at the ER Membrane. Annual review of cell and developmental biology. 1999; 15 (1): 799–842. Available from: https://doi.org/10.1146/annurev.cellbio.15.1.799.
  10. Haryadi R, et al. Optimization of Heavy Chain and Light Chain Signal Peptides for High Level Expression of Therapeutic Antibodies in CHO Cells. PloS one. 2015; 10 (2). Available from: http://dx.doi.org/10.1371/journal.pone.0116878.
  11. Marschall ALJ, et al. Targeting antibodies to the cytoplasm. mAbs. 2011; 3 (1): 3–16. Available from: https://doi.org/10.4161/mabs.3.1.14110.
  12. Richardson JH, Wayne MA. Intracellular antibodies: development and therapeutic potential. Trends in biotechnology. 1995; 13 (8): 306– 10. Available from: https://doi.org/10.1016/S0167-7799(00)88970-2.
  13. Plotnikova MA., i dr. scFv-fragmenty rekombinantnyh antitel k virusu grippa: poluchenie i harakteristika funkcional'noj aktivnosti. BIOpreparaty. Profilaktika, diagnostika, lechenie. Prinyato k publikacii 12.12.2025. Available from: https://doi.org/10.30895/2221-996X-2025-728. Russian.
  14. Killian ML. Hemagglutination assay for influenza virus. Animal influenza virus. Animal Influenza Virus. Methods in Molecular Biology. 2014; 1161: 3–9. Available from: https://doi.org/10.1007/978-1-4939-0758-8_1.
  15. Plotnikova MA, et al. Antibody microarray immunoassay for screening and differential diagnosis of upper respiratory tract viral pathogens. Journal of Immunological Methods. 2020; 478: 112712. Available from: https://doi.org/10.1016/j.jim.2019.112712.
  16. Corti D, et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science. 2011; 333 (6044): 850–6. Available from: https://doi.org/10.1126/science.1205669.
  17. Krivitskaya VZ, et al. Detection and Differentiation of Current Influenza B Viruses by the Microculture Enzyme-Linked Immunosorbent Assay Using Monoclonal Antibodies. Applied Biochemistry and Microbiology. 2023; 59 (7): 1039–46. Available from: https://doi.org/10.1134/S0003683823070037.
  18. Biswas M, et al. Broadly neutralizing antibodies for influenza: Passive immunotherapy and intranasal vaccination. Vaccines. 2020; 8 (3): 424. Available from: https://doi.org/10.3390/vaccines8030424.
  19. Momont C, et al. A pan-influenza antibody inhibiting neuraminidase via receptor mimicry. Nature. 2023; 618 (7965): 590–7. Available from: https://doi.org/10.1038/s41586-023-06136-y.
  20. Heaton NS, et al. Genome-wide mutagenesis of influenza virus reveals unique plasticity of the hemagglutinin and NS1 proteins. Proceedings of the National Academy of Sciences. 2013; 110 (50): 20248–53. Available from: https://doi.org/10.1073/pnas.1320524110.
  21. Klasse PJ. Neutralization of Virus Infectivity by Antibodies: Old Problems in New Perspectives. Advances in biology. 2014; 2014 (1): 157895. Available from: https://doi.org/10.1155/2014/157895.
  22. Yamaizumi M, et al. Neutralization of diphtheria toxin in living cells by microinjection of antifragment A contained within resealed erythrocyte ghosts. Cell. 1978; 13 (2): 227–32. Available from: https://doi.org/10.1016/0092-8674(78)90191-5.
  23. Tonegawa S. Somatic generation of antibody diversity. Nature. 1983; 302 (5909): 575–81. Available from: https://doi.org/10.1038/302575a0.
  24. Burke B, Warren G. Microinjection of mRNA coding for an anti-golgi antibody inhibits intracellular transport of a viral membrane protein. Cell. 1984; 36 (4): 847–56. Available from: https://doi.org/10.1016/0092-8674(84)90034-5.
  25. Cottignies-Calamarte A, Tudor D, Bomsel M. Antibody Fc-chimerism and effector functions: When IgG takes advantage of IgA. Frontiers in immunology. 2023; 14: 1037033. Available from: https://doi.org/10.3389/fimmu.2023.1037033.
  26. Tiller KE, Tessier PM. Advances in Antibody Design. Annual review of biomedical engineering. 2015; 17 (1): 191–216. Available from: https://doi.org/10.1146/annurev-bioeng-071114-040733.
  27. Helfrich W, et al. A rapid and versatile method for harnessing scFv antibody fragments with various biological effector functions. Journal of Immunological Methods. 2000; 237 (1–2): 131–45. Available from: https://doi.org/10.1016/s0022-1759(99)00220-3.
  28. Ahmad ZA, et al. scFv antibody: Principles and clinical application. Journal of Immunology Research. 2012; 2012 (1): 980250. Available from: https://doi.org/10.1155/2012/980250.
  29. Le Gall F, et al. Di-, tri- and tetrameric single chain Fv antibody fragments against human CD19: Effect of valency on cell binding. FEBS letters. 1999; 453 (1–2): 164–8. Available from: https://doi.org/10.1016/S0014-5793(99)00713-9.
  30. Kabayama H, et al. An ultra-stable cytoplasmic antibody engineered for in vivo applications. Nature communications. 2020; 11 (1): 336. Available from: https://doi.org/10.1038/s41467-019-13654-9.
  31. Marschall ALJ, Dübel S, Böldicke T. Specific in vivo knockdown of protein function by intrabodies. MAbs. 2015; 7 (6): 1010–35. Available from: https://doi.org/10.1080/19420862.2015.1076601.
  32. Karikó K, et al. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity. 2005; 23 (2): С. 165–75. Available from: https://doi.org/10.1016/j.immuni.2005.06.008.
  33. Sahin U, Karikó K, Türeci Ö. mRNA-based therapeutics-developing a new class of drugs. Nature reviews Drug discovery. 2014; 13 (10): 759–80. Available from: https://doi.org/10.1038/nrd4278.
  34. Jin Q, et al. The protective effect of a combination of human intracellular and extracellular antibodies against the highly pathogenic avian influenza H5N1 virus. Human Vaccines & Immunotherapeutics. 2022; 18 (1): 2035118. Available from: https://doi.org/10.1080/21645515.2022.2035118.
  35. Mukhtar MM, et al. Single-chain intracellular antibodies inhibit influenza virus replication by disrupting interaction of proteins involved in viral replication and transcription. The international journal of biochemistry & cell biology. 2009; 41 (3): 554–60. Available from: https://doi.org/10.1016/j.biocel.2008.07.001.
  36. Ashour J, et al. Intracellular expression of camelid single-domain antibodies specific for influenza virus nucleoprotein uncovers distinct features of its nuclear localization. Journal of virology. 2015; 89 (5): 2792–800. Available from: https://doi.org/10.1128/JVI.02693-14.
  37. Blavier J, et al. Targeting viral replication complexes with mRNA-encoded nanobodies: a new frontier for antiviral design. Drug Discovery Today. 2025; 104531. Available from: https://doi.org/10.1016/j.drudis.2025.104531.